CA19-9 As a Prognostic Biomarker in Pancreatic Neuroendocrine Tumors Abstract #1434

Introduction: Carbohydrate antigen19-9 (CA19-9) is generally not considered as a biomarker in pancreatic neuroendocrine tumors (pNETs) since most pNETs present with normal range of CA19-9.
Aim(s): The current study was to evaluate the role of serum CA19-9 levels as a prognostic factor in a relative large number of patients with pNETs.
Materials and methods: Consecutive patients were retrospectively collected from a single institution between June 2006 and February 2015. The receiver operating characteristic (ROC) curve and area under the ROC curve were used to select the best cut-off values for baseline CA19-9 levels. The primary end point was overall survival. Potential factors related to abnormal elevation of CA19-9 in pNETs were also investigated.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Kaizhou Jin

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1432 Neutrophil-Lymphocyte Ratio Predicts Survival in Pancreatic Neuroendocrine Tumors
Introduction: Although the prognostic role of neutrophil-lymphocyte ratio (NLR) has been confirmed in a variety of tumors, the prognostic role of NLR in pancreatic neuroendocrine tumors (PNETs) has not been examined.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Kaizhou Jin
Authors: Luo G, Jin K, Liu C, Lu Y, ...
#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations
Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Dr Anguraj Sadanandam
#1161 Comparative Proteomic Analysis of Human Insulinoma and Its Clinical Implications in Pancreatic Neuroendocrine Tumors
Introduction: Insulinoma is the most common functional PNET. Its molecular tumorigenesis is largely unknown and proteomic study on insulinoma has not been reported
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Yuan-Jia Chen
Authors: Qiao X W, Song Y L, Bai C M, Zhu L M, ...
#2114 Significance of Biochemical Testing in Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNETs) are rare tumors that are frequently diagnosed late in the course of the disease. Several biomarkers have been proposed in the literature for diagnosis in patients with these tumors.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Doctor Azka Athar
Authors: Athar A, ...
#663 Comparing Chinese Pancreatic Neuroendocrine Tumors with Americans: Their Clinicopathological Features and Prognosis
Introduction: It is unknown if clin-patho features of PNET pts are different between China and USA, the largest country in the east and west, respectively.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Dr. X.W. Qiao
Authors: Qiao X W, Tang L, Zhu L M, Chen J, ...